Bristol-Myers Squibb To Pay $19.5M Over Abilify Marketing
By John Kennedy (December 8, 2016, 5:08 PM EST) -- Bristol-Myers Squibb will pay $19.5 million to 42 states and Washington, D.C., to settle claims that the company allegedly improperly marketed the antipsychotic drug Abilify, multiple states' attorneys general announced Wednesday.
The states including New York, Texas and California claimed that BMS improperly promoted Abilify for use by children and certain elderly patients and also misrepresented the findings of scientific studies done on the drug, which led to a misrepresentation of the risks Abilify posed to patients, including weight gain. BMS, which said it has not marketed the drug since 2013, did not admit any wrongdoing and denied all the allegations...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!